News & Events

• MGB Biopharma Announces Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3, a Potential New Gold Standard, First-Line Treatment for Clostridioides difficile Infection (CDI) January 27, 2021
• MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI) May 19, 2020
• MGB Biopharma Presents at INV€$TIVAL SHOWCASE 2019 December 3, 2019
• MGB Biopharma to Attend Upcoming BioEurope Meeting in Hamburg on 11 to 13 Nov 2019 October 29, 2019
• MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3 October 11, 2019
• MGB Biopharma Announces Completion of Funding Round August 30, 2019
• Bio-Europe 2019 June 12, 2019
• ASM Microbe 2019 June 12, 2019
• Bio International Convention 2019 June 3, 2019
• BioEquity 2019 May 20, 2019